Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Depreciation & Amortization (CF) (2018 - 2025)

UroGen Pharma's Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $75000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 10.29% year-over-year to $75000.0; the TTM value through Dec 2025 reached $347000.0, down 11.25%, while the annual FY2025 figure was $307000.0, 6.69% down from the prior year.
  • Depreciation & Amortization (CF) reached $75000.0 in Q4 2025 per URGN's latest filing, down from $100000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $217000.0 in Q1 2023 to a low of $68000.0 in Q4 2024.
  • Average Depreciation & Amortization (CF) over 5 years is $157450.0, with a median of $195500.0 recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 132.93% in 2021, then tumbled 63.83% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then dropped by 6.0% to $188000.0 in 2023, then crashed by 63.83% to $68000.0 in 2024, then grew by 10.29% to $75000.0 in 2025.
  • Per Business Quant, the three most recent readings for URGN's Depreciation & Amortization (CF) are $75000.0 (Q4 2025), $100000.0 (Q3 2025), and $100000.0 (Q2 2025).